Applied UV installs patented LumiCide surface disinfection solution at Mt. Sinai Medical Center in New York Morningside

One of the most prestigious hospitals in the world

Applied UV, Inc. (NasdaqCM: AUVI ) (“Applied UV” or the “Company”), a pathogen removal technology company that applies the power of narrow range ultraviolet (“UVC”) light for surfaces and catalytic bioconversion technology for the purifying air to destroy pathogens safely, thoroughly, and automatically, announces that its wholly-owned subsidiary SteriLumen has just initially installed its patented LumiCide UVC disinfection systems for surfaces and drains in 17 patient rooms at the famous Mt. Sinai Medical Center Morningside. Mount Sinai Morningside formerly known as Mount Sinai St. Luke’s, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City.

Mt. Sinai plans to publish the results in an academic paper later this summer, which would further validate independent results obtained previously and conducted by ResInnova Laboratories. This validation could facilitate the adoption of our LumiCide surface and drain disinfection solutions in healthcare facilities worldwide.

Mount Sinai Morningside is affiliated with the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, a nonprofit hospital system formed by the merger of Continuum Health Partners and Mount Sinai Medical Center in September 2013. It provides facilities general medical and surgical facilities, ambulatory care, and a level 2 trauma center, verified by the American College of Surgeons. It operates 21 clinics and as of 2020, is nationally ranked by US News and World Report .

John F. Andrews, CEO and Director of Applied UV, said, “We welcome Mt. Sinai Medical Center to the Applied UV family. our patented disinfection products (air and surface) further testify to the proven effectiveness but also to the growing interest of globally recognized brands and companies that use our family of solutions to protect their facilities, employees and products against harmful airborne and surface particles. related pathogens. We look forward to a long and fruitful relationship with the Mount Sinai team.

The LumiCide Disinfection System product line has the following attributes:

• Focus on sink area and drain . Focuses on pathogens that accumulate on the sink area including handles, faucets and backsplash and in the drain.
• Destruction of pathogens UVC LED . Destroys 4 logs (99.99%) of some of the most dangerous pathogens like COVID 19, MERSA C’diff, in the bathroom sink/sink area with at least two hours of continuous use.
• Automatic operation . Built-in programmable controller that ensures operation for the entire required daily time and is not dependent on manual operation.
• Continuous operation . Works in cycles of two hours on and four hours off, except for the disinfectant drain which is turned on for 15 minutes every hour. The synchronization protocol is managed by a programmable controller and a motion detector included in each device and works while the room is still occupied and while the bathroom is not in use, therefore, continuously disinfecting an area continued heavy contamination.
• Security . The built-in motion sensor and sensor automatically turn off the UVC light when someone enters the room, eliminating any UV safety concerns. Once there is no movement in the room for 10 minutes, the UVC light will turn back on to restart and continue its cycle.
• Removable UVC LED panel . UVC LEDs are installed via a removable panel, making it easy to replace or upgrade.
• Ease of installation . The unit is easy to install and uses standard electrical wiring.
• IoT connectivity . IOT connectivity uses Wi-Fi and RF technology which will enable the continuous transmission of usage and functionality data over the internet for collection and analysis.

Internal Applied UV research and research provided by the CDC estimate that each year approximately 1 in 25 hospitalized patients in the United States (approximately 1.4 million Americans) are diagnosed with at least one infection related to only hospital care and additional infections occur in other health facilities. About 900,000 Americans die each year from complications associated with hospital-acquired infections. Many HAIs are caused by the most urgent and severe antibiotic resistant (AR) bacteria and can lead to life-threatening sepsis. According to the NIH, healthcare-associated infections are known to increase length of stay, healthcare costs, and mortality. Each year, the top 5 nosocomial infections result in costs of approximately $9.8 billion.

About Applied UVs

Applied UV is focused on developing and acquiring technologies that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Connected Platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, completely and automatically, addressing the challenge of hospital-acquired infections (“HAI”). Intended for use in high customer turnover facilities such as hospitals, hotels, commercial facilities and other public spaces, the company’s Lumicide™ platform uses UVC LEDs in several patented designs for the infection control in and around high traffic areas, including sinks and toilets, killing bacteria, viruses and other pathogens residing on hard surfaces near appliances. The company’s patented drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical, pathogen-intensive location. SteriLumen’s Airocide® air purifying devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II medical device, uses proprietary photocatalytic bioconversion (PCO) technology that draws air into a reaction chamber that converts harmful molds, microorganisms, pathogens into airborne, destructive VOCs, allergens, odors and biogases into harmless water vapor and green carbon dioxide without producing ozone or other harmful by-products. Airocide® applications include healthcare, hospitality, grocery chains, winemaking facilities, commercial real estate, schools, dental offices, post-harvest, grocery stores, facilities of cannabis and houses. For more information about Applied UV, Inc. and its affiliates, please visit the following websites: https://www.applieduvinc.com

Forward-looking statements

The information contained in this document may contain “forward-looking statements”. Forward-looking statements reflect current beliefs about future events. When used in this press release, the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements in this press release regarding Applied UV’s management views regarding its business strategy, future results of operations and outlook for cash and capital resources. Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical facts nor guarantees of future performance. We therefore caution you against relying on any of these forward-looking statements. Factors or events that could cause the Company’s actual results to differ may arise from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including United States securities laws, the Company does not intend to update forward-looking statements to conform them to actual results.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220614005359/en/

Applied UV Inc.
John F. Andrews
CEO and Director of Applied UV
john.andrews@applieduvinc.com

Brett Maas, General Manager
R.I. Hayden
brett@haydenir.com
(646) 536-7331